TABLE 3.
Percent changes in lipid variables from baseline to week 8.
| Variable | TRE (No. = 33) | RE (No. = 31) | T (No. = 32) |
|---|---|---|---|
| LDL‐C | |||
| Mean (SD) | −61.38 (14.25) | −58.18 (22.17) | −4.49 (19.09) |
| Treatment difference | |||
| LS mean (SE) | −62.56 (4.16) | −59.93 (4.06) | – |
| LS mean (SE) | −54.97 (3.49) | – | −0.17 (3.23) |
| LS mean difference [95% CI] | – | −2.63 [−12.08, 6.82] | −54.80 [−62.76, −46.83] |
| p † | – | .5790 | <.0001 |
| Total cholesterol | |||
| Mean (SD) | −45.24 (12.41) | −41.75 (16.73) | −2.32 (13.60) |
| Treatment difference | |||
| LS mean (SE) | −45.33 (3.27) | −42.71 (3.18) | – |
| LS mean (SE) | −40.31 (2.53) | – | 1.40 (2.40) |
| LS mean difference [95% CI] | – | −2.62 [−9.97, 4.73] | −41.72 [−47.56, −35.87] |
| p † | – | .4784 | <.0001 |
| Triglyceride | |||
| Mean (SD) | −27.37 (30.11) | −29.21 (30.11) | 18.38 (45.94) |
| Treatment difference | |||
| LS mean (SE) | −24.29 (5.55) | −26.42 (5.60) | – |
| LS mean (SE) | −27.13 (7.97) | – | 17.87 (7.70) |
| LS mean difference [95% CI] | – | 2.13 [−10.85, 15.11] | −45.00 [−63.96, −26.05] |
| p† | – | .7436 | <.0001 |
| HDL‐C | |||
| Mean (SD) | 3.04 (14.93) | 8.54 (14.55) | −3.12 (12.75) |
| Treatment difference | |||
| LS mean (SE) | 3.09 (3.08) | 7.64 (3.05) | – |
| LS mean (SE) | 1.69 (2.79) | – | −3.20 (2.77) |
| LS mean difference [95% CI] | – | −4.55 [−11.33, 2.22] | 4.89 [−1.82, 11.61] |
| p† | – | .1836 | .1500 |
Treatment difference was calculated as telmisartan/rosuvastatin/ezetimibe group minus rosuvastatin/ezetimibe group or telmisartan group.
Abbreviations: CI, Confidence Interval; LS mean, Least Square Mean; RE, rosuvastatin/ezetimibe; SD, Standard Deviation; SE, Standard Error; T, telmisartan; TRE, telmisartan/rosuvastatin/ezetimibe.
†
p value for ANCOVA, with Group(stratification variable) as a covariate.